公共头尾

Among a newer generation of scientists representing the entire chemical spectrum, from chemical engineering and materials to chemical biology, K. Barry Sharpless is known for click chemistry, a term he coined in 1998. Inspired by the complexity nature achieves from a handful of building blocks, Sharpless started actively looking in the mid-90s for a way to discover new chemical connectivity and reactivity. Click chemistry did not gain momentum until his group's discovery of CuAAC (the copper-catalyzed azide-alkyne cycloaddition), a near-perfect reaction (2002). Recently the Sharpless group discovered SuFEx, also near-perfect for click chemistry. In concert with the thiol-ene reaction, these three make click chemistry a far-reaching method for drug discovery, chemical biology, and materials science.

In 1963, K. Barry Sharpless graduated from Dartmouth College, where he was introduced, most fortuitously, to the wonders of chemistry by T. A. Spencer. Following graduate research with E. E. van Tamelen at Stanford University, Sharpless completed postdoctoral studies with J. P. Collman, also at Stanford, and at Harvard University with Konrad Bloch.

Sharpless set up his own laboratory in 1970 at the Massachusetts Institute of Technology. Except for several years in the 1970s when he was a member of Stanford’s chemistry faculty, Sharpless remained at MIT until moving to the Scripps Research Institute (TSRI) in 1990. At TSRI he is a W. M. Keck Professor of Chemistry and a member of the Skaggs Institute for Chemical Biology.

Ding Kuiling is a deputy to the 14th National People's Congress (NPC). He concurrently served as the Executive Director of the Chinese Chemical Society (CCS), Vice President of the China Industry-University-Research Institute Collaboration Association (CIUR), and Vice Chairman of the Standing Committee of the Shanghai Association for Science and Technology (SAST). He previously held several positions at the Shanghai Institute of Organic Chemistry (SIOC) in the Chinese Academy of Sciences, including Director, Deputy Director, Chairman of the Trade Union, Deputy Secretary of the Party Committee, and Secretary of the Discipline Inspection Commission. Then he served as Vice President of ShanghaiTech University, Dean of ShanghaiTech Colleges, and member of the Party Standing Committee, and Executive Vice President of Shanghai Jiao Tong University. He is mainly engaged in the research of asymmetric reactions and green organometallic chemistry. He has proposed and successfully applied new concepts and methods of chiral catalyst design, and developed new chiral ligands and catalysts with characteristic frameworks.

Wu Peng is a Professor in the Department of Molecular Medicine. Dr. Wu received his doctorate from the Scripps Research in 2005 under the guidance of Prof. K. Barry Sharpless. From August 2005 to September 2008, Dr. Wu was a postdoctoral fellow in the group of Prof. Carolyn R. Bertozzi at the University of California, Berkeley. There, he combined his interests in bioorthogonal chemistry and biotechnology by developing a method for site-specific modification of monoclonal antibodies using a genetically encoded aldehyde tag. The research in the Wu laboratory integrates synthetic chemistry with glycobiology to explore the cellular and molecular mechanisms that control immune responses toward cancer and human pathogens.

Dong Jiajia was born in China and received his B.A. from Xiamen University in 2000. Prof. Jiang Biao supervised his 2006 Ph.D. in organic chemistry from the Shanghai Institute of Organic Chemistry (SIOC). He was a senior scientific researcher at Egret Pharma, Shanghai, before becoming a postdoctoral associate in 2009–2015 with Prof. K. Barry Shappless's group at Scripps Research. During his postdoctoral work at Scripps Research, Jiajia discovered the 'Sulfur(VI) Fluoride Exchange (SuFEx) reaction' with Professor Sharpless. He is currently a professor at Shanghai Jiao Tong University. His research interests mainly focus on 'SuFEx click chemistry.

Dr. Shui Wenqing is leading a research group of G protein-coupled receptor (GPCR) Omics & Ligand Discovery. The main research interest of Shui Group is to develop high-throughput affinity MS techniques for the discovery of GPCR ligands with new chemical scaffolds and unique pharmacological properties. This affinity MS-based platform, when combined with omics technology or modular click chemistry, enables the discovery of a variety of new GPCR modulators from either synthetic libraries or natural herb extracts. Meanwhile, Shui Group has established experimental and bioinformatics approaches for in-depth transmembrane proteome profiling to facilitate potential drug target discovery from the GPCR superfamily.

Among a newer generation of scientists representing the entire chemical spectrum, from chemical engineering and materials to chemical biology, K. Barry Sharpless is known for click chemistry, a term he coined in 1998. Inspired by the complexity nature achieves from a handful of building blocks, Sharpless started actively looking in the mid-90s for a way to discover new chemical connectivity and reactivity. Click chemistry did not gain momentum until his group's discovery of CuAAC (the copper-catalyzed azide-alkyne cycloaddition), a near-perfect reaction (2002). Recently the Sharpless group discovered SuFEx, also near-perfect for click chemistry. In concert with the thiol-ene reaction, these three make click chemistry a far-reaching method for drug discovery, chemical biology, and materials science.

In 1963, K. Barry Sharpless graduated from Dartmouth College, where he was introduced, most fortuitously, to the wonders of chemistry by T. A. Spencer. Following graduate research with E. E. van Tamelen at Stanford University, Sharpless completed postdoctoral studies with J. P. Collman, also at Stanford, and at Harvard University with Konrad Bloch.

Sharpless set up his own laboratory in 1970 at the Massachusetts Institute of Technology. Except for several years in the 1970s when he was a member of Stanford’s chemistry faculty, Sharpless remained at MIT until moving to the Scripps Research Institute (TSRI) in 1990. At TSRI he is a W. M. Keck Professor of Chemistry and a member of the Skaggs Institute for Chemical Biology.

Tang Ben Zhong received Ph.D. degree from Kyoto University and conducted postdoctoral research at the University of Toronto. He is now a Presidential Chair Professor at the Chinese University of Hong Kong, Shenzhen. He was elected to the Chinese Academy of Sciences in 2009. He is currently serving as Editor-in-Chief of Aggregate published by Wiley. His research interests include materials science and biomedical theranostics. He has received many awards, such as the National Natural Science Award (2017), the Nano Today Award (2021) and Biomaterials Global Impact Award (2023). His publications have been cited over 176,000 times, with an h-index of 185. He has been listed as a Highly Cited Researcher since 2014 in both areas of Chemistry and Materials Science.

Mingxuan obtained his B.S. and M.S. degrees from the School of Life Science and Biotechnology at Shanghai Jiao Tong University. He received his Ph.D. degree in chemistry from Princeton University under the supervision of Dorothea FIEDLER. Next, he joined the Phil COLE lab for postdoc training at Johns Hopkins University School of Medicine and later moved to Harvard Medical School Brigham and Women’s Hospital. He was appointed to the Department of Chemistry at Westlake University in 2019 as an assistant professor.

Katsunori Tanaka received his Ph.D. (2002) from Kwansei Gakuin University, Japan, under the direction of Prof. Shigeo Katsumura. After a post-doc with Prof. Koji Nakanishi at Columbia University (2002–2005), he joined Professor Koichi Fukase's group at Osaka University as an Assistant Professor. He moved to RIKEN as an Associate Chief Scientist in 2012. He was then appointed as a Chief Scientist, at RIKEN Cluster for Pioneering Research in 2017 and as a Professor in the Department of Chemical Science and Engineering, Tokyo Institute of Technology (2019), under the cross-appointment system. He received several awards including Best Electric Guitar Player under 20 in Japan (1994), Young Scientist's Research Award in the 2nd Natural Product Chemistry Symposium (2002), Young Scientist's Research Award in the 46th Chemistry of National Products (2004), Young Investigator's Award in the 46th Japanese Society of Carbohydrate Research (2010), Incentive Award in the Society of Synthetic Organic Chemistry, Japan (2011), American Chemical Society (ACS) Division of Carbohydrate Chemistry, Horace S. Isbell Award (2015), JSPS Prize (2018), the Chemical Society of Japan (CSJ) Award for Creative Work (2019), Astellas Award for the Best Biomedical Research (2022), and Kaneka Life Science Industrial Award in the Society of Synthetic Organic Chemistry, Japan (2023).

Gao Bing earned his Ph.D. in 2014 from the Shanghai Institute of Organic Chemistry under the guidance of Prof. Hu Jinbo. His doctoral research primarily focused on the development of novel reagents and methodologies for integrating fluorine-containing modules into functional molecules. In early 2015, he commenced his post-doctoral fellowship at Scripps Research in San Diego, where he collaborated with Prof. K. Barry Sharpless in the field of sulfur fluoride exchange reactions. In 2019, he joined Hunan University as a Joint Professor in the Chemistry Department and the State Key Laboratory.

Dong Jiajia was born in China and received his B.A. from Xiamen University in 2000. Prof. Jiang Biao supervised his 2006 Ph.D. in organic chemistry from the Shanghai Institute of Organic Chemistry (SIOC). He was a senior scientific researcher at Egret Pharma, Shanghai, before becoming a postdoctoral associate in 2009–2015 with Prof. K. Barry Shappless's group at Scripps Research. During his postdoctoral work at Scripps Research, Jiajia discovered the 'Sulfur(VI) Fluoride Exchange (SuFEx) reaction' with Professor Sharpless. He is currently a professor at Shanghai Jiao Tong University. His research interests mainly focus on 'SuFEx click chemistry.

Dr. Chen Xing is currently a Changjiang Distinguished Professor and Dean of the College of Chemistry and Molecular Engineering at Peking University. He completed his bachelor's degree in chemistry from Tsinghua University in 2002 and his Ph.D. in chemistry from the University of California, Berkeley in 2007, under the guidance of Prof. Carolyn Bertozzi and Prof. Alex Zettl. He then joined the laboratory of Prof. Timothy Springer at Harvard Medical School as a LSRF postdoctoral fellow, where his research focused on structural immunology. Dr. Chen started as an Assistant Professor of Chemistry at Peking University in 2010 and was promoted directly to Full Professor with tenure in 2016. He is also affiliated with Center for Life Science (CLS) and the Synthetic and Functional Biomolecule Center (SFBC) of Peking University. Some of his recent awards include the Zhang Shuzheng Award for Outstanding Achievements in Glycoscience (2021), the ACS Horace S. Isbell Award (2021), the Xplore Prize (2010), Tan Kah Kee Young Scientist Award (2020), CCS-RSC Young Chemist Award (2018), and ACS David Y. Gin New Investigator Award (2016). His current research interest focuses on chemical glycobiology.

Dr. Peng Wenjie has been a principal investigator of Shanghai Center for Systems Biomedicine at Shanghai Jiao Tong University since 2018. He received his Ph.D. in Organic Chemistry from Dalian Institute of Chemical Physics jointly with Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences under the supervision of Prof. Yu Biao in 2006. Then, he joined Prof. Todd Lowary laboratory at University of Alberta as a postdoc fellow, and later worked at Scripps Research (Consortium for Functional Glycomics and Prof. James Paulson laboratory).
In recent years, by using multi-disciplinary approach, his lab is focusing on development of glycan-based probes to investigate the biological functions of glycan-binding proteins, e.g., Siglecs (Sialic acid-binding immunoglobulin-like lectins) and viral spike proteins (from influenza viruses, coronaviruses, etc.), which mediate human diseases.

Dr. Yang Yi received his doctorate from Peking University in 2017 under the guidance of Prof. Chen Peng. From July 2017 to November 2019, Dr. Yang was a postdoctoral fellow in the group of Prof. Wu Peng and Prof. K. Barry Sharpless. After his postdoctoral training, Dr. YANG started his independent career in the industry. He is the CEO and founder of Glyco-therapy Biotechnology Co., Ltd., a start-up company in Hangzhou. The research in Yang's group focuses on combining glycoengineering with protein chemistry to develop a conjugation platform for the construction of multi-specific drugs for therapeutic applications. This platform has been used by biotechs and biopharmas to develop the next generation of antibody-drug conjugates.

Wu Peng is a Professor in the Department of Molecular Medicine. Dr. Wu received his doctorate from the Scripps Research in 2005 under the guidance of Prof. K. Barry Sharpless. From August 2005 to September 2008, Dr. Wu was a postdoctoral fellow in the group of Prof. Carolyn R. Bertozzi at the University of California, Berkeley. There, he combined his interests in bioorthogonal chemistry and biotechnology by developing a method for site-specific modification of monoclonal antibodies using a genetically encoded aldehyde tag. The research in the Wu laboratory integrates synthetic chemistry with glycobiology to explore the cellular and molecular mechanisms that control immune responses toward cancer and human pathogens.

Dr. Wang Chu received Ph.D. in 2007 from the University of Washington under the guidance of Prof. David Baker, training in the area of computational protein structural prediction and design. He then worked as a postdoctoral fellow with Prof. Benjamin Cravatt at Scripps Research, Lo Jolla, and developed multiple chemical proteomic methods to profile reactive cysteines and modifications in proteomes. In 2014, he joined Peking University to start his independent career and was promoted to Tenured Professor of Chemical Biology in 2020. He has won the Young Chemical Biologist Award from the International Chemical Biology Society and the Distinguished Young Scholar Award from the National Natural Science Foundation of China. His research interest is to develop chemical and computational proteomics methods to enable quantitative profiling of functional enzymes, protein post-translational modifications as well as protein-ligand interactions in proteomes.

Dr. Chen Peng obtained a BS degree in Chemistry at Peking University in 2002, and a Ph.D. in Chemistry with Prof. He Chuan at The University of Chicago in 2007. After a postdoctoral training at Scripps Research with Prof. Peter Schultz, he started his independent career at Peking University in 2009. He is currently the Director of the Chemical Biology Division at the Chinese Chemical Society and the Executive Editor of ACS Chemical Biology. His research interest is at the interface of Chemistry and Biology.
His lab is a leading group in developing bioorthogonal cleavage reactions for chemically controlled protein activation and profiling in living systems. This has created a new direction in bioorthogonal chemistry for the gain-of-function study of proteins under living conditions. He employed this toolkit to study how the spatial-temporal organized human proteome is rewired during cancer and immune signaling, and his lab also exploited the potential of these new reactions in protein-based therapy.

Aye received her combined B.S. and M.S. degree in Chemistry at the University of Oxford, UK, in 2004, and Ph.D. degree in Organic Chemistry with Prof. David Evans from Harvard University, in 2009. She then switched her research discipline to life science and trained with Prof. JoAnne Stubbe at MIT. Science in the AYE lab (https://leago.epfl.ch) – established in mid-2012 –seeks to understand non-canonical cell signaling processes. Her laboratory is most well-known for investigations into electrophile signaling, a nuanced communication mode whereby on-target engagement between reactive metabolites and target proteins, orchestrates precision responses at cellular/organismal levels. Contributions from here laboratory have been recognized by several international honors, with the most recent being the 2021 ACS Cope Scholars, International Chemical Biology Society Global Lectureship, 2022 Tetrahedron Young Investigator, and European Research Council grant awards.

Xue Min graduated from Nanjing University with a B.S. in Chemistry. He obtained his Ph.D. in Chemistry from UCLA under the guidance of Prof. Jeffrey Zink, working on supramolecular drug delivery systems and excited-state mixed-valence analysis. He then conducted postdoctoral research at Caltech in Prof. Jim Heath's group, switching to the fields of single-cell analysis and systems biology. In 2016, he started his independent career in the Department of Chemistry at UC Riverside and was promoted to Associate Professor with tenure in 2022. His current research focuses on developing molecular tools for biomedical applications. His work is recognized by the NIBIB Trailblazer Award, the NIGMS MIRA, and the DoD Career Development Award.

Dr. Shui Wenqing is leading a research group of G protein-coupled receptor (GPCR) Omics & Ligand Discovery. The main research interest of Shui Group is to develop high-throughput affinity MS techniques for the discovery of GPCR ligands with new chemical scaffolds and unique pharmacological properties. This affinity MS-based platform, when combined with omics technology or modular click chemistry, enables the discovery of a variety of new GPCR modulators from either synthetic libraries or natural herb extracts. Meanwhile, Shui Group has established experimental and bioinformatics approaches for in-depth transmembrane proteome profiling to facilitate potential drug target discovery from the GPCR superfamily.

Prof. Rouhanifard received her B.S. in Biochemistry and Molecular Biology from UMassAmherst in 2007. She then completed a Ph.D. in Biochemistry at theAlbert Einstein College of Medicine under the supervision ofWu Peng, developing chemical tools to probe glycosylation in cells using biorthogonal chemistry. She then joined the laboratory ofArjun Raj Bioengineering department at the University of Pennsylvania as a postdoctoral associate and a NIH Ruth S. Kirschstein F32 National Research ServiceAward fellow,where she developed single-molecule approaches to image RNAin cells. She joined the Northeastern Bioengineering department as an Assistant Professor in 2019. Her primary research interests lie in understanding the epitranscriptome and related mecha-nisms that govern cellular differentiation and response to external stimuli. The Rouhanifard laboratory develops quantitative, single-molecule sequencing and imaging approaches using new chemistry to identify and perturb sites of RNAmodifications to reveal specific biological functions that may be exploited for the development of future therapeutics.

Prof. Wang Lei received BS and MS from Peking University, and PhD from UC Berkeley mentored by Peter G. Schultz. His graduate research resulted in the first expansion of the genetic code to include unnatural amino acids (Uaas) in 2001, for which he was awarded the Young Scientist Award by the Science magazine. After postdoctoral training with Roger Y. Tsien (Nobel Laureate in Chemistry), Wang started his group at the Salk Institute in 2005 and moved to University of California San Francisco in 2014. His group has developed new methods for the expansion of the genetic code in a variety of cells and animals. Wang discovered that release factor one is nonessential in E. coli, and engineered autonomous bacteria capable of incorporating Uaas at multiple sites with high efficiency. Recently, Wang pioneered the concept of proximity-enabled bioreactivity and demonstrated the genetic encoding of latent bioreactive Uaas in live systems. This new class of Uaas enables bioreactivities, inaccessible to proteins before, to be specifically introduced into biosystems, opening the door to harnessing covalent chemistry for protein engineering and biological research in vivo. Wang is a Top Young Innovator (by MIT Technology Review), a Basil O'Connor Starter Scholar, a Beckman Young Investigator, a Searle Scholar, an NIH Director's New Innovator Awardee, and a recipient of the Emil Thomas Kaiser Award.

Dr. John Zhang earned his Ph.D. degree in the United States from EVMS and continued on two consecutive postdoctoral trainings for an additional five years at The Johns Hopkins University School of Medicine in Molecular Biology and OSU in Molecular Virology, respectively. Currently, he is a Chief Operation Officer and Executive Vice President at Cheerland Precision Medicine Group. Dr. Zhang returned to work in China in 2016 and served as a vice president of manufacturing operation and process development at Qilu Pharmaceutical followed by working as VP at BeiGene and Zai Lab Incorporations in charge of Manufacturing & Process technology development. Before returning to China, he worked for Lonza Biologics in the US engaging in PC/PV studies & supporting 20k-L bioreactor manufacturing operation, and for Bio-Techne group in charge of manufacturing operation. Dr. Zhang has more than 25 years of experience in both basic research at the University of Illinois at Chicago as an Assistant Professor for 7 years and biologics drug development in pharmaceuticals in the last 14 years. He has also published more than 25 peer-reviewed papers in journals and developed a few commercialized biologics products in the US.